CytomX Therapeutics 3Q Loss/Shr 9c >CTMX
Story updates
09:18:05 PM UTC
SquawkNews
CytomX ended Q3 with $348M in cash, cash equivalents and investments and expects runway into 2H 2028. Varseta-M received FDA Fast Track designation; Q3 revenue was $1.7M versus $6.0M a year earlier.Material DetailsContext by AI AnalystThis is a clinical-stage oncology company funding an expanding V…